Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Advances Diabetic Foot Infection Trial to Pivotal Phase 3
Recce Pharmaceuticals expands diabetic foot infection trial to Phase 3, broadening recruitment and adding below-knee ulcers; dual Australia-Indonesia program.
Recce Pharmaceuticals Signs Distribution Agreement for R327 Diabetic Foot Gel across MENA
Recce inks 10-year exclusive MENA licensing deal for R327G diabetic foot gel; upfront fees up to $5m, 30% net sales, Phase III data eyed for year-end approval.
Recce Pharmaceuticals Commences Phase 3 Trial of Topical Gel for Diabetic Foot Infections
Recce Pharmaceuticals (ASX: RCE) has commenced patient dosing for a registrational Phase 3 clinical trial of its RECCE 327 topical gel (R327G) to treat diabetic foot infections (DFI). The company has activated five clinical study sites across one of the world’s largest DFI patient populations in Indonesia, where estimates place the prevalence of diabetes at 20.9 […]
ASX Investment Opportunities on Show in Singapore During Grand Prix
All roads will lead to Singapore in early October with the important Spark Plus Aussie Equities Day investment show being staged in the lead-up to the local grand prix motoring event. The 2025 Spark Plus Aussie Equities Day is the 4th installment of their flagship event which aims to introduce a range of Australian companies to […]